Cereno Scientific’s Board of Directors and Management Enter Lock-up Agreements

Nyheter Cereno Scientific Nyheter alla bolag

Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här

Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Cereno Scientific’s Board of Directors and Management Enter Lock-up Agreements

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that all members of its board of directors and management have signed lock-up agreements for their shares and/or other securities in the company until and including December 31, 2026.

All members of the company’s board of directors and management have entered into agreement not to sell their shares and/or other securities in the company in any way, also known as lock-up agreements, during the period until and including December 31, 2026. The lock-up prevents transfer or disposal of shares and/or other securities in the company, with certain exceptions.

“The decision by all members of the Board of Directors and management to enter into lock-up agreements is a clear expression of our shared long-term commitment to Cereno Scientific. The company is at an important stage, with a strengthened position, significant clinical and regulatory progress, and ongoing business development and partnering activities. Through these commitments, we want to demonstrate our confidence in the company’s strategy and our focus on creating long-term value for shareholder,” said Jeppe Øvlesen, Chairperson of the Board of Directors, Cereno Scientific.

“We have strong momentum at Cereno Scientific, with important clinical and regulatory priorities ahead of us and intensified partnering activities. The decision by all members of the Board of Directors and management to enter into lock-up agreements demonstrates our strong confidence in the company’s future development and our shared ambition to create value for shareholders. We fully support the strategy and remain focused on leveraging the opportunities enabled by the company’s strengthened position,” said Sten R. Sörensen, CEO and board member of Cereno Scientific.

About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. The company’s innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12 months of treatment and showed that a majority of patients completing treatment maintained or improved clinical status. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed favorable safety and tolerability profile in Phase I, development focus for Phase II is pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also advancing the preclinical program CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist shown to prevent thrombosis without increased bleeding risk, currently being evaluated in antiphospholipid syndrome (APS).

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.

Datum	2026-07-02, kl 07:45
Källa	MFN

Bifogade filer

PDF

LOGGA IN

Cereno Scientific

Affiliate

Cereno Scientific’s Board of Directors and Management Enter Lock-up Agreements